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Low income countries like Ethiopia are underrepresented in clinical research. As a major public commitment to
clinical research, Ethiopia celebrated the International Clinical Trial Day (ICTD) for the first time on 20 May 2014
under the auspices of Addis Ababa University. The motto for the day was ‘Clinical Trials for Excellence in Patient
Care’. The celebration offered an opportunity to inform academic staff, researchers, students and the leadership
about clinical trials being conducted and to discuss the future of clinical trials in the country. Although clear
challenges to the conduct of trials abound, clinical trials registered from Ethiopia in trial registration databases is
increasing. Cross-country collaborations, international funding support, motivation of academic staff to conduct
clinical trials and the commitment and engagement of the leadership in research are all improving. The overall
impact of clinical trials is also encouraging. For example, some of the trials conducted in Ethiopia have informed
treatment guidelines. However, administrative capacity, research infrastructure as well as financial support remain
weak. There is a need for enhanced university-industry linkage and translation of research findings into locally
relevant evidence. Ethiopia, as well as the whole of Africa, has an unparalleled opportunity to lead the way in
clinical trials, given its prospect of development and the need to have locally relevant evidence for its growing
population. In this commentary we reflect on the celebration of ICTD, the status and opportunities for conducting
clinical trials and the way forward for facilitating clinical trials in Ethiopia and Africa.
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Ethiopia, with a population of over 90 million [1], is the
second most populous country in Africa. Despite its
tumultuous past, the country has shown potential for
growth and change in recent years. For example, it is the
second leading country in the world in terms of gains
in life expectancy in the past two decades [2]. It has also
made substantial gains in reducing maternal mortality
[3] and child mortality [4]. The health system, focused on
prevention and primary care, has also shown promising
progress [5]. The number of medical schools has grown
from three to over 30 in just two decades.* Correspondence: abe.wassie@kcl.ac.uk
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unless otherwise stated.The broad national indicators of progress happening
in Ethiopia make it one of the most promising countries
in Africa to conduct clinical trials. Within this context,
Ethiopia celebrated its first International Clinical Trial
Day (ICTD) on 20 May 2014, with the motto of ‘Clinical
Trials for Excellence in Patient Care’ (Figure 1). The
ICTD was hosted by the College of Health Sciences at
Addis Ababa University, and was commemorated with
various presentations of ongoing clinical trials within
the college, ranging from landmark trials on visceral
leishmaniasis [6,7] to randomized trials of schizophrenia
[8,9]. The establishment of a state of the art bioequivalence
laboratory, only the second in Africa, was also celebrated
on this occasion. We took this opportunity to reflect
on the conduct of clinical trials in Ethiopia and Africa
[10], and we hoped that these reflections may have
resonance for other low income countries, particularly in
sub-Saharan Africa.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Motto for the celebration of the International Clinical Trial Day, Addis Ababa, Ethiopia.
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Clinical trials in Africa and Ethiopia
The global disparity in clinical research capacity and
service provision may be indicated simply through the
share of clinical trials a country or a region has registered
in clinical trial registry databases. We have called this the
‘clinical trials index’ (CTI). For example, the share of
studies registered from Africa (in Clinicaltrials.gov) is
only 0.02%, although the region represents about 15%
of the population of the world. Within Africa, most of the
clinical trials are conducted in South Africa (47.3%), which
makes one of the largest financial investments on health
and has a relatively well-developed health system in Africa
[11]. Only a limited number of clinical trials are registered
from Ethiopia in trial registration sites, representing only
1.5% of all the studies from Africa. These CTI figures are
crude reflections of the disparity in clinical research and
service capacities within Africa and the world at large.
Despite the limited number, some of the studies from
Ethiopia were very important. For example, the World
Health Organization (WHO) recommended sodium
stibogluconate and paromomycin as first line treatments
for visceral leishmaniasis in East Africa, based on clinical
trials conducted in Ethiopia as part of an East African
consortium (Leishmaniasis East Africa Platform (LEAP))
[12]. Equally important was the differential response
pattern of leishmaniasis within the East African countries
[12]. For example, in assessing the response to different
formulations of stibogluconate, it was found that the
response rate was lower among the Ethiopian sample
[13]. Patients with HIV co-infection also had very poor
treatment response [7]. Differential treatment response
was also demonstrated between different regions within
Ethiopia, partly accounted for by nutritional status [14].
This clearly underscores the need to have locally relevant
evidence for different populations and the need for expertise
in clinical trials in each country. Understandably, most of
the clinical trials conducted in Ethiopia were for infectious
diseases (Figures 2 and 3). However, clinical trials for
non-communicable diseases (NCD) are also very important.
First, NCDs are becoming increasingly relevant, and given
their chronicity, are likely to take a big share of the healthinvestment of any country. Underscoring the relevance of
NCDs was a major focus on the United Nations Assembly
in September 2011 [15]. NCDs have been considered a
leading cause of death in all world regions with rapidly
increasing burden [16]. In the context of the ‘double
transition’, Africa is likely to be disproportionately affected
by NCDs. Secondly, treatment of NCDs is likely to require
more local adaptations than treatment of infectious
conditions. Thirdly, the ethical requirements for the
conduct of clinical trials for NCDs, particularly those
that rely on non-medication interventions or those
looking at secondary indications of existing treatments,
are likely to be different.
Ethics procedures in Ethiopia
Ethiopia has relatively advanced ethics procedures and
review processes to protect participants in research.
Various ethics committees are established at the level
of institutions and there is one national committee.
The national-level ethics committee, the National Research
Ethics Review Committee (NRERC) [17], handles proposals
with complex interventions and those with potentially
higher risk to participants. All drug trials are also referred
to the NRERC and drug trials are also regulated by the
Food Medicine and Healthcare Authority of Ethiopia [18],
which has the ultimate authority. The guidelines and
terms of references of the ethics committees draw on
international codes such as the Nuremberg Code, Belmont
Report, the International Conference on Harmonization
[19], Declaration of Helsinki and the Council for
International Organizations of Medical Sciences. The
Ethiopian Bioethics Initiative (ETBIN) was recognized as
the first national chapter of the Pan-African Bioethics
Initiative (PABIN). Its by-laws were recommended as
templates for sister chapters in Africa [20].
Challenges and opportunities of conducting clinical trials
in Ethiopia and other African countries
A Strength, Weakness, Opportunity and Threat (SWOT)
analysis matrix is presented in Figure 4. The challenges of
conducting clinical trials in Ethiopia and other African
countries partly relate to the unique requirements of
Figure 2 Strength Weakness Opportunity and Threat (SWOT) analysis of the context for clinical trials in Ethiopia.
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have applicability to conducting research in general. These
include lack of appropriate infrastructure, for example
space, supplies and maintenance; weak administrative
capacity; lower prioritization of research in academic
institutions given the need to produce a university
educated work force; limited university-industry linkage;Figure 3 Comparative proportion of trials for non-infectious
and infectious diseases in Ethiopia (N = 59). Based on data
available at Clinicaltrials.gov (on 28 June 2014).limited sources of funding; and the lack of equitable
incentives for researchers.
Regulatory frameworks are either underdeveloped or
imported directly without consideration of the local
context. Regulatory functions are frequently slow and
bureaucratic. However, plenty of opportunities exist
for the conduct of clinical trials both in Ethiopia and
other African countries. Research is receiving increasing
recognition, particularly in some academic institutions;
there is better networking and international collaboration,
a massive expansion of medical schools and healthcare
services, use of technology is improving and the generally
improving economy in Ethiopia and many African countries
are more conducive for conducting clinical research.
Discussion
The way forward
It is in Africa’s best interest to commit to clinical trials
both to serve its people, its region and the world at
large. Specific recommendations are listed below. Within
Ethiopia, a recommendation was made to establish a
clinical trial committee, which would conduct needs
assessments, explore opportunities for collaboration,
assess priority areas for clinical trials in line with the
country’s priorities and make recommendations for
effective establishment of leading clinical trial centers
in the country. The main threats to conducting clinical
trials are the poor administrative capacity in many institu-
tions, the lack of expertise and brain drain to international
institutions and non-governmental organizations (NGOs)







Figure 4 Proportion of clinical trials conducted in specific subject or disease area in Ethiopia (N = 59). Based on data available at
Clinicaltrials.gov (on 28 June 2014).
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extremely limiting administrative capacity that hinders the
conduct of clinical trials. Institutions and governments
should address these needs urgently. Clinical trials should
be grounded in solid ethical principles and should be con-
ducted for the benefit of patients.
Recommendations on conducting clinical trials in low
income settings
Clinical trials have the potential to benefit patients,
institutions and nations if they are conducted with the
right tools. Therefore all interested medical institutions
should be encouraged to participate in the conduct of
clinical trials. The following recommendations are meant
to support institutional engagement in clinical trials:
1. Trials should be for patients’ benefit at all times.
Competent regulatory frameworks should be able to
scrutinize trials whether the principle of beneficence
and non-maleficence are upheld. People in low
income countries are particularly vulnerable owing
to poverty, low education and restrained political
empowerment. Therefore, stringent regulatory
frameworks are required.
2. Even when regulatory frameworks have to be
stringent, they also have to be efficient, especially in
the context of international collaborations.
3. Both research and administrative capacity
limitations are significant threats to the conduct of
clinical trials. International collaborations should
therefore support both administrative and research
capacity development.4. We would like to go even further. If international
institutions or industries are interested in working
with low income institutions in conducting clinical
trials, they should consider it their ethical
responsibility to support both human and material
capacity development in low income countries
before embarking on serious clinical trials.
5. Although the priority of clinical trials in low
income countries will be on infectious diseases,
it is important to understand that interventions
(or the delivery mechanisms) for non-communicable
disease require even more local contextualization.
Considering this need for contextualization and the
increasing burden they cause, it is not too early to
focus attention on these diseases.
6. All institutions interested in participating in clinical
trials should be encouraged to do so. Establishing
institutional clinical trial committees may help to
support capacity development, collaborations and
setting priorities.
7. These institutions should also be prepared to be
subject to regulatory standards set by local and
international regulatory bodies. Full transparency
and accountability in relation to registering trial
protocols, monitoring and reporting are minimum
standards.
8. Regulatory frameworks need to be contextualized for
the country and treatment being considered.
Several measures to strengthen frameworks for the
protection of patients, particularly the most vulnerable,
in the area of clinical trials has been a main agenda of
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uphold these principles. The implementation of these
principles in practice needs to be facilitated. We
support full transparency in the conduct of clinical
trials, including registration on web-based clinical
trial registration databases. However, these regulatory
frameworks have to be contextualized and relevant
for the country and for the specific study [21]. Regu-
latory authorities should be supported to have the
capacity and the confidence to make contextualized
decisions, particularly in the context of international
collaborations.
Finally, to the best of our knowledge, this is the first
celebration of its kind in Africa. It might help for countries
to celebrate the ICTD annually, both as an opportunity to
celebrate clinical trials, and as an occasion to unite and
push for the goal of improving the life of patients through
clinical trials.Conclusions
Local evidence is essential and is more likely to influence
policy and practice [22,23]. There are some promising
signs of progress in clinical research in Africa. For
example, there is now the Pan-African Clinical Trials
Registry [24], which is an important resource for
clinical trials in Africa. The East African Consortium
for Clinical Research [25], composed of five East
African and five European countries, is another initiative
that may support clinical trials in Africa. The number of
clinical trials and investment in research is increas-
ing. However, research in general, and clinical trials
in particular lag far behind in Africa. This is demon-
strated by the extremely low CTI. Attention should
be paid to scaling up clinical trials, not only in
infectious conditions, but also in NCDs. Strengthening
regulatory frameworks to support researchers and
protect participants should be encouraged. Establishing
clinical trial units and human capacity development are
essential ingredients to scaling up clinical trials in
Africa. Researchers work in extremely difficult work-
ing environments, with limited support from the sys-
tem. If clinical trials are to flourish, as they should,
researchers have to be supported to focus on the
delivery of clinical trials. Celebrating ICTD provides
an important platform to create awareness and to
advocate on behalf of clinical trials, researchers and
patients.
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